The Reproductive Medicine Center was established in 2000 and became one of the first three units in Guangdong Province and the first qualified center in Shenzhen to carry out in vitro fertilization technology in 2002. In 2017, it was approved as one of the "Three Projects" for medical and health care in Shenzhen, and introduced the research team of female reproductive health and fertility protection, led by Academician Qiao Jie from the Reproductive Medicine Department of Peking University Third Hospital. In 2018, it became the first center in Shenzhen to obtain qualifications to carry out third-generation in vitro fertilization technology (pre implantation genetic testing technology, PGT). In 2019, it was approved to build a Class B department for the "Peak Discipline" in Guangdong Province's high-level hospital construction. For over 20 years, the center has been awarded multiple times as a characteristic specialty in Guangdong Province, a brand discipline in Shenzhen, and a key medical specialty in Shenzhen.
The central outpatient department includes: clinical departments for women, clinical departments for men, and day wards. The central laboratory includes AIH laboratory, IVF laboratory, PGT laboratory, urology laboratory, and research laboratory. There are currently 53 professional and technical personnel, including 20 clinical doctors, 13 laboratory technicians, 16 nurses, and 4 researchers; There are 18 doctoral students and 14 master's students.
In the past three years, the average annual outpatient volume has exceeded 150000 people, and there have been over 7000 assisted reproductive cycles for in vitro fertilization. We have advanced equipment worth nearly 20 million yuan, including Astec ICI dual workstation, mobile IVF workstation, inverted microscope and micro operation system, time difference embryo detection and analysis system, genetic workstation, spindle observation instrument, cell electrofusion instrument, embryo culture box, storage type liquid nitrogen tank, and live cell workstation.
Specialized advantages and technologies: intrauterine artificial insemination, in vitro fertilization embryo transfer, intracytoplasmic sperm injection, frozen thawed embryo transfer, pre implantation genetic testing, immature egg in vitro maturation culture, assisted hatching, vitrification cryopreservation of eggs and embryos, and cryopreservation of sperm and ovarian tissue. Male surgery: Testicular biopsy, testicular microsurgical sperm extraction, vas deferens anastomosis, vas deferens epididymal anastomosis, seminal vesicle exploration, microsurgical varicocele ligation and other techniques.
Featured diagnosis and treatment projects: 1. Pre implantation genetic diagnosis technology: can identify the carrying status of balanced translocations in embryos and block the transmission of chromosomal balanced translocations to offspring. Block the transmission of thousands of genetic diseases such as familial thalassemia, hereditary deafness, polycystic kidney disease, and spinal muscular atrophy (SMA) in offspring. 2. Fertility protection technology: Cryopreservation of ovarian tissue, eggs, and embryos can effectively solve the fertility problems of cancer patients after chemotherapy or radiotherapy; 3. Embryo implantation window endometrial receptivity and uterine microbiota detection technology provide accurate and effective diagnosis and treatment plans for difficult infertility such as repeated implantation failures and recurrent miscarriage.
The Reproductive Medicine Center will fully leverage its collaborative innovation capabilities, break down disciplinary and field barriers, conduct high-quality clinical diagnosis, treatment, and research around reproductive health-related diseases, improve the success rate of assisted reproduction for difficult and infertile patients in the center, and continue to play a leading role in the discipline in Shenzhen and surrounding cities.